Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Orchard Therapeutics Plc ADR (NQ: ORTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 16.52 (1) Ask (Size) 17.13 (1) Prev. Close 16.70 Today's Range N/A - N/A 52wk Range 15.94 - 16.65 Shares Outstanding 184,260,149 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 May 07, 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List May 03, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Performance More News Read More Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy March 20, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics: Q3 Earnings Insights November 13, 2023 Via Benzinga Why Orchard Therapeutics Stock Is Soaring Today October 05, 2023 Via The Motley Fool Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. March 18, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome February 05, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium February 02, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy January 25, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases January 24, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD December 11, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH November 30, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX November 28, 2023 From Kahn Swick & Foti, LLC Via Business Wire Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments November 13, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023 October 26, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023 October 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Sarepta Therapeutics Stock Showing Rising Relative Strength October 09, 2023 Via Investor's Business Daily ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX October 06, 2023 From Kahn Swick & Foti, LLC Via Business Wire Crude Oil Down 2%; ConAgra Brands Earnings Top Views October 05, 2023 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Thursday's Intraday Session October 05, 2023 Via Benzinga Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session October 05, 2023 Via Benzinga Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast October 05, 2023 Via Benzinga Topics Stocks Exposures US Equities Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double October 05, 2023 Via Investor's Business Daily Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 October 05, 2023 Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM) October 05, 2023 From Brodsky & Smith LLC Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
